🇺🇸 FDA
Patent

US 8716473

Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase

granted A61PA61P35/00A61P43/00

Quick answer

US patent 8716473 (Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase) held by SENTINEL ONCOLOGY LIMITED expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SENTINEL ONCOLOGY LIMITED
Grant date
Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P35/00, A61P43/00